The Hong Kong Society of Rheumatology Consensus Recommendations for the Management of Gout

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2023 Apr 4

PMID 37014501

Authors

Ronald Ml Yip

Tommy T Cheung

Ho So

Julia Ps Chan

Carmen Tk Ho

Helen Hl Tsang

Carrel Kl Yu

Priscilla Ch Wong

Affiliations

Soon will be listed here.

Abstract

Gout is one of the most common noncommunicable diseases in Hong Kong. Although effective treatment options are readily available, the management of gout in Hong Kong remains suboptimal. Like other countries, the treatment goal in Hong Kong usually focuses on relieving symptoms of gout but not treating the serum urate level to target. As a result, patients with gout continue to suffer from the debilitating arthritis, as well as the renal, metabolic, and cardiovascular complications associated with gout. The Hong Kong Society of Rheumatology spearheaded the development of these consensus recommendations through a Delphi exercise that involved rheumatologists, primary care physicians, and other specialists in Hong Kong. Recommendations on acute gout management, gout prophylaxis, treatment of hyperuricemia and its precautions, co-administration of non-gout medications with urate-lowering therapy, and lifestyle advice have been included. This paper serves as a reference guide to all healthcare providers who see patients who are at risk and are known to have this chronic but treatable condition.

Citing Articles

Management of gout in primary care of Hong Kong in accordance with international guidelines: any gaps to bridge?.

Chan K, Chiang L, Ho K, Li Y, Ko S, Chen C BMC Prim Care. 2025; 26(1):38.

PMID: 39939917 PMC: 11817381. DOI: 10.1186/s12875-024-02664-2.

Targeting Neutrophil Extracellular Traps in Gouty Arthritis: Insights into Pathogenesis and Therapeutic Potential.

Li C, Wu C, Li F, Xu W, Zhang X, Huang Y J Inflamm Res. 2024; 17:1735-1763.

PMID: 38523684 PMC: 10960513. DOI: 10.2147/JIR.S460333.

References

Saito Y, Stamp L, Caudle K, Hershfield M, McDonagh E, Callaghan J . Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2015; 99(1):36-7. PMC: 4675696. DOI: 10.1002/cpt.161. View

Hershfield M, Callaghan J, Tassaneeyakul W, Mushiroda T, Thorn C, Klein T . Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2012; 93(2):153-8. PMC: 3564416. DOI: 10.1038/clpt.2012.209. View

Li R, Yu K, Li C . Dietary factors and risk of gout and hyperuricemia: a meta-analysis and systematic review. Asia Pac J Clin Nutr. 2018; 27(6):1344-1356. DOI: 10.6133/apjcn.201811_27(6).0022. View

Bardin T . Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015; 82(3):141-3. DOI: 10.1016/j.jbspin.2015.01.002. View

Pui K, Gow P, Dalbeth N . Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013; 40(6):872-6. DOI: 10.3899/jrheum.121301. View

Baraf H, Becker M, Gutierrez-Urena S, Treadwell E, Vazquez-Mellado J, Rehrig C . Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013; 15(5):R137. PMC: 3979037. DOI: 10.1186/ar4318. View

Roddy E, Zhang W, Doherty M . The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007; 3(8):443-9. DOI: 10.1038/ncprheum0556. View

Choi H, Soriano L, Zhang Y, Garcia Rodriguez L . Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012; 344:d8190. PMC: 3257215. DOI: 10.1136/bmj.d8190. View

Dalbeth N, Saag K, Palmer W, Choi H, Hunt B, MacDonald P . Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017; 69(12):2386-2395. PMC: 5725733. DOI: 10.1002/art.40233. View

10.

Mackenzie I, Ford I, Nuki G, Hallas J, Hawkey C, Webster J . Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396(10264):1745-1757. DOI: 10.1016/S0140-6736(20)32234-0. View

11.

Krishnan E . Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012; 7(11):e50046. PMC: 3507834. DOI: 10.1371/journal.pone.0050046. View

12.

Becker M, Schumacher Jr H, Wortmann R, MacDonald P, Eustace D, Palo W . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450-61. DOI: 10.1056/NEJMoa050373. View

13.

Schlesinger N, Detry M, Holland B, Baker D, Beutler A, Rull M . Local ice therapy during bouts of acute gouty arthritis. J Rheumatol. 2002; 29(2):331-4. View

14.

Baker J, Krishnan E, Chen L, Schumacher H . Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?. Am J Med. 2005; 118(8):816-26. DOI: 10.1016/j.amjmed.2005.03.043. View

15.

Siu Y, Leung K, Ka-Hang Tong M, Kwan T . Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2005; 47(1):51-9. DOI: 10.1053/j.ajkd.2005.10.006. View

16.

Lee M, Graham G, Williams K, Day R . A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?. Drug Saf. 2008; 31(8):643-65. DOI: 10.2165/00002018-200831080-00002. View

17.

Ghosh P, Cho M, Rawat G, Simkin P, Gardner G . Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken). 2013; 65(8):1381-4. DOI: 10.1002/acr.21989. View

18.

Shoji A, Yamanaka H, Kamatani N . A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004; 51(3):321-5. DOI: 10.1002/art.20405. View

19.

Nardin M, Verdoia M, Pergolini P, Rolla R, Barbieri L, Schaffer A . Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. Nutr Metab Cardiovasc Dis. 2016; 26(7):567-574. DOI: 10.1016/j.numecd.2016.03.001. View

20.

van Durme C, Wechalekar M, Buchbinder R, Schlesinger N, van der Heijde D, Landewe R . Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014; (9):CD010120. DOI: 10.1002/14651858.CD010120.pub2. View